Physician profile
Ann C Morrill
NPI 1104928225
$11,993.65
in general payments reported to CMS, 2019-2025
50 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,121 · 2020: $910 · 2021: $2,679 · 2022: $482 · 2023: $694 · 2024: $1,575 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,802.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,718.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,349.82 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Biohaven Pharmaceuticals, INC. | $1,267.06 | 2021 | |
| Abbvie INC. | $1,113.27 | 2019-2025 | |
| Amgen INC. | $795.60 | 2019-2025 | Repatha, Tepezza, Krystexxa |
| Lilly USA, LLC | $657.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $477.88 | 2019-2025 | |
| Esperion Therapeutics, INC. | $388.66 | 2020-2023 | Nexletol |
| Janssen Pharmaceuticals, INC | $350.72 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $347.11 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Allergan, INC. | $330.61 | 2019-2020 | |
| Amarin Pharma, INC. | $276.96 | 2019-2022 | |
| Corcept Therapeutics | $232.42 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $200.00 | 2019-2020 | |
| Pfizer INC. | $191.73 | 2019 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Morrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.